RA

Global Healthy Living Foundation to Present Pioneering Patient-Centered Research at ACR Convergence 2023

Retrieved on: 
星期四, 十一月 9, 2023
Biometrics, Telemedicine, Virtual Medicine, Pharmaceutical, General Health, Health, Wearables, Mobile Technology, Technology, Other Health, Online, Rheumatism, American College, Hospital, Treatment, Face, Doctor of Philosophy, Medicine, Disease, Efficacy, COVID-19, Overalls, Culture, PRO, Pain, Medical Affairs Bureau, Gold, MPH, Impact, Additive effect, RA, American College of Rheumatology, Data management, Exercise, Patient, ACR, Plant, Rehabilitation, MD, Motivation, Mindfulness, Quality of life, Longitudinal study, Research, Osteoporosis, DSM-IV codes, Guideline, Rheumatoid arthritis, Role, TNF inhibitor, Pros, Conjoint analysis, Jaki, Poster, Ageing, WEAR, Pharmaceutical industry, Medical device, Medical imaging, Nursing, Dietary supplement, Diet, Rheumatology, Fatigue, Flare, Epidemiology, Arthritis

The Global Healthy Living Foundation and its digital, arthritis patient centered research registry, formerly ArthritisPower, will collaboratively present eight scientific abstracts and five patient perspective posters at the American College of Rheumatology Convergence 2023 (Philadelphia, PA, November 10-15, 2023).

Key Points: 
  • The Global Healthy Living Foundation and its digital, arthritis patient centered research registry, formerly ArthritisPower, will collaboratively present eight scientific abstracts and five patient perspective posters at the American College of Rheumatology Convergence 2023 (Philadelphia, PA, November 10-15, 2023).
  • Collectively, GHLF researchers will focus on innovative approaches to remote therapeutic monitoring, patient engagement, and personalized care in rheumatic and musculoskeletal diseases.
  • This study offers key insights on innovative disease tracking methods, including those that can happen outside traditional clinical settings, particularly for diseases like rheumatoid arthritis (RA).
  • GHLF anticipates engaging with fellow organizations and professionals at ACR Convergence to share their year-long accomplishments in rheumatic disease research.

Revolo Biotherapeutics Presents New Data on ‘1805 at the American College of Rheumatology Convergence 2023 Annual Conference

Retrieved on: 
星期二, 十一月 7, 2023
Rheumatology, American College, Conference, Inflammation, Cell, RA, San Diego Convention Center, University, Immune system, Gene, Clinical & Translational Immunology, Autoimmunity, Patient, Pharmaceutical industry, Vaccine

NEW ORLEANS and CAMBRIDGE, United Kingdom, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that new preclinical data on ‘1805 will be presented via two posters at the American College of Rheumatology Convergence 2023 Annual Conference, which is being held November 10–15 at the San Diego Convention Center in San Diego, CA.

Key Points: 
  • “These preclinical data provide further insights into ‘1805’s differentiated mechanism of action,” said Jonathan Rigby, Revolo’s Chief Executive Officer.
  • “While current RA treatments can in part ameliorate joint destruction, they are limited in the ability to prevent osteoclast-induced bone destruction.
  • In addition, ‘1805 normalizes the expression of genes abnormally activated in cells from RA patients, such as those associated with inflammation.
  • Altogether, the data support the clinical potential of ‘1805 and its further clinical evaluation.

Blackbird Labs, a Next-Generation Life Sciences Accelerator, Launches with $100 Million and Foundational Collaboration with Johns Hopkins University

Retrieved on: 
星期二, 十一月 7, 2023
UMB, Colitis, DSM-IV codes, History of the University of Maryland, College Park, Innovation, Crohn's disease, Johns Hopkins University, RNA, Johns Hopkins, Biotechnology, Laboratory, University of Maryland, College Park, Research, Inflammation, RA, Lieber Institute for Brain Development, Drug development, Senior, Scripps Research, Clinical trial, Economic development, Ecosystem, Schizophrenia, Messenger, University, Senior advisor, Cancer, Entrepreneurship, Economy, Patient, Pharmaceutical industry, Management

BALTIMORE, Nov. 7, 2023 /PRNewswire/ -- Blackbird Laboratories, Inc. ("Blackbird Labs"), a next-generation life sciences accelerator, today announced that it has launched with a $100 million founding grant from The Stephen and Renee Bisciotti Foundation and research collaborations with Johns Hopkins University, the University of Maryland, Baltimore, and the Lieber Institute for Brain Development. Blackbird Labs' mission is to accelerate the development and commercialization of novel medicines and cutting-edge technologies to enhance the well-being of patients facing unmet medical needs.   

Key Points: 
  • Blackbird Labs provides capital, program management, and strategic scientific and business input from its newly recruited team of life sciences professionals, seeking to bridge the gap between pioneering academic science and industry.
  • Blackbird Labs is led by Matt Tremblay, Ph.D., the CEO and a founding member of the board of directors since Blackbird Labs' creation in January 2023.
  • Blackbird Labs launches with a world-class group of advisors spanning the global life sciences venture investment community and business leaders.
  • "Blackbird Labs is an exciting new element of our innovation ecosystem, a unique resource for funding and expertise to help bring Johns Hopkins technologies to market.

Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
星期一, 十一月 6, 2023
Janus, Research, Lilly, Eli Lilly and Company, AD, Plasma, Half-life, PD, Psoriatic arthritis, Washington University in St. Louis, Biomarker, JAK3, EPI, G&A, Health, Rheumatoid arthritis, MAD, JAK, R, RA, ITK, ACRS, Ulcerative colitis, Osteoporosis, Pharmacokinetics, Hidradenitis suppurativa, PK, Methotrexate, Pancreatic cancer, Safety, Atopic dermatitis, Collection, Chapter 11, Title 11, United States Code, Therapy, Patient, MK2, Pharmaceutical industry, Vaccine, Palladium, Cryptocurrency, Rare-earth element, Tobacco, Hydraulic machinery

WAYNE, Pa., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the third quarter of 2023 and provided a corporate update.

Key Points: 
  • Net loss was $29.3 million for the third quarter of 2023 compared to $20.0 million for the third quarter of 2022.
  • Total revenue was $9.3 million for the third quarter of 2023 compared to $19.0 million for the third quarter of 2022.
  • Research and development (R&D) expenses were $23.9 million for the quarter ended September 30, 2023 compared to $23.7 million for the prior year period.
  • General and administrative (G&A) expenses were $7.1 million for the quarter ended September 30, 2023 compared to $5.8 million for the corresponding prior year period.

Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
星期四, 十一月 2, 2023
Week, Therapy, CDAI, BTLA, Atopic dermatitis, PD-1, Patient, Rheumatoid arthritis, RA, SAN, Ulcerative colitis, Pharmaceutical industry

Initiated a global Phase 2b trial to treat rheumatoid arthritis (RA) with rosnilimab, our PD-1 agonist

Key Points: 
  • Initiated a global Phase 2b trial to treat rheumatoid arthritis (RA) with rosnilimab, our PD-1 agonist
    SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the third quarter ended September 30, 2023 and provided a business update.
  • “We’ve made strong progress this quarter executing against our multi-year plan to develop best-in-class immune cell modulators to drive differentiated clinical outcomes in heterogeneous, systemic autoimmune and inflammatory diseases,” said Daniel Faga, president and chief executive officer of Anaptys.
  • The decrease relates to cash used for the $50 million stock repurchase program and operating activities.
  • The increase was due primarily to manufacturing and development costs for rosnilimab, ANB032 and ANB033.

Sonoma Biotherapeutics to Present Preclinical Data from Novel Treg Therapy for Rheumatoid Arthritis at American College of Rheumatology Convergence 2023

Retrieved on: 
星期一, 十一月 6, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, CAR, American College, MPH, Northwest Biotherapeutics, Inflammation, Rheumatoid arthritis, Protein, RA, Joint, Blood, American College of Rheumatology, Autoimmunity, Synovial fluid, Patient, ACR, Pharmaceutical industry, Vaccine, Regulatory T cell

Sonoma Biotherapeutics, Inc. , a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, will present preclinical data from its autologous chimeric antigen receptor (CAR) Treg therapy product candidate for the treatment of rheumatoid arthritis (RA) at the American College of Rheumatology (ACR) Convergence 2023, taking place in San Diego, California from November 10-15th.

Key Points: 
  • Sonoma Biotherapeutics, Inc. , a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, will present preclinical data from its autologous chimeric antigen receptor (CAR) Treg therapy product candidate for the treatment of rheumatoid arthritis (RA) at the American College of Rheumatology (ACR) Convergence 2023, taking place in San Diego, California from November 10-15th.
  • “Our CAR-Treg product candidate, SBT-77-7101, is designed to target proteins that accumulate in the joints and blood of patients with RA,” said Mark D. Eisner, M.D., MPH, Chief Medical Officer of Sonoma Biotherapeutics.
  • “Results from this study show that we can detect CAR-reactive citrullinated antigens in both synovial fluid and blood.
  • In addition, these protein levels correlated with systemic markers of inflammation.

Renesas’ New Ultra-High Performance MCUs are Industry’s First Based on Arm Cortex-M85 Processor

Retrieved on: 
星期二, 十月 31, 2023
Semiconductor, Engineering, Technology, Manufacturing, Software, Hardware, Cortex, ECC, CTI Electronics Corporation, Octal, Architecture, XIP, TCM, FIPS, AI, Winning Combination, Memory, Internet of things, ARM Cortex-A53, Intelligence, PSA, NIST, MCU, RA, Feminism and modern architecture, Internet, PLC, ARM Cortex-M, Ecosystem, Machine learning, Embedded, Silicon, Combination, Smartglasses, CAVP, Reality, Center for Advanced Security Research Darmstadt, Family, Arm, ARM architecture family, Comparison of multi-paradigm programming languages, Multimedia, Mantra, DSP, Senior, FSP, MPU, Coremark, SE, ML, BSP, Video game, Medical device, Renesas Electronics, Helium, Ethernet

The new RA8 Series MCUs are the industry’s first to implement the Arm® Cortex®-M85 processor, enabling the new devices to deliver industry-leading 6.39 CoreMark/MHz1 performance.

Key Points: 
  • The new RA8 Series MCUs are the industry’s first to implement the Arm® Cortex®-M85 processor, enabling the new devices to deliver industry-leading 6.39 CoreMark/MHz1 performance.
  • This level of performance will allow system designers to use the RA MCUs in applications that previously required microprocessors (MPUs).
  • The new series is part of Renesas’ popular RA Family of MCUs based on Arm Cortex processors.
  • View the full release here: https://www.businesswire.com/news/home/20231031195413/en/
    The new RA8 Series MCUs deploy Arm Helium™ technology, Arm’s M-Profile Vector Extension that provides up to a 4X performance boost for digital signal processor (DSP) and machine learning (ML) implementations versus MCUs based on the Arm Cortex-M7 processor.

Klein & Hoffman, Inc. Announces Addition of Experienced Professionals to the Enclosure and BECx Division

Retrieved on: 
星期五, 十一月 3, 2023
Government, Julie Hesmondhalgh, Ball, CXA, LEED, Officer (armed forces), History, College of Engineering (University of Nebraska–Lincoln), Architecture, Municipal government of Toronto, Federation, Data, RA, Ball State University, Pay-for-Performance (Federal Government), Higher education, AIA, Boston Architectural College, NCARB, Commercial, John Scott-Scott, K&H, University, University of Illinois System, CDT, Management, Interior design, Health care

He also has a commendable 24-year military service tenure as a Naval Officer.

Key Points: 
  • He also has a commendable 24-year military service tenure as a Naval Officer.
  • Pete Power, RA, President of Klein & Hoffman, expressed his enthusiasm for the new hires, highlighting how seamlessly they integrate with the firm's longstanding dedication to excellence in building enclosure.
  • The addition of Scott, Scott, and Nick creates a powerful synergy with our established principles and core values, propelling Klein & Hoffman into an even brighter future."
  • Glenn Johnson, AIA, NCARB, QCxP, Principal, added, "This addition complements and enhances our existing strengths.

ADGM introduces the world's first DLT Foundations Regime

Retrieved on: 
星期四, 十一月 2, 2023
Register, Dame Alice Owen's School, Heart, Distributed ledger technology law, ABU, Distributed ledger, National Database and Registration Authority, RA, DLT, Cryptocurrency, Blockchain

This new regime comes in line with ADGM's strategy to foster initiatives in the broader blockchain and digital asset realm.

Key Points: 
  • This new regime comes in line with ADGM's strategy to foster initiatives in the broader blockchain and digital asset realm.
  • By harnessing the potential of technology, ADGM's DLT Foundations Regime offers an effective means to organise and promote governance whilst recognising the industry's need for decentralisation.
  • The introduction of the DLT Foundations Regime marks a revolutionary step forward, reinforcing ADGM's commitment to a proactive approach rooted in extensive cross-industry dialogue and collaboration with various stakeholders.
  • To view the full details of the Distributed Ledger Technology (DLT) Foundations Regulations 2023, please click HERE

ADGM introduces the world's first DLT Foundations Regime

Retrieved on: 
星期四, 十一月 2, 2023
Register, Dame Alice Owen's School, Heart, Distributed ledger technology law, ABU, Distributed ledger, National Database and Registration Authority, RA, DLT, Cryptocurrency, Blockchain

This new regime comes in line with ADGM's strategy to foster initiatives in the broader blockchain and digital asset realm.

Key Points: 
  • This new regime comes in line with ADGM's strategy to foster initiatives in the broader blockchain and digital asset realm.
  • By harnessing the potential of technology, ADGM's DLT Foundations Regime offers an effective means to organise and promote governance whilst recognising the industry's need for decentralisation.
  • The introduction of the DLT Foundations Regime marks a revolutionary step forward, reinforcing ADGM's commitment to a proactive approach rooted in extensive cross-industry dialogue and collaboration with various stakeholders.
  • To view the full details of the Distributed Ledger Technology (DLT) Foundations Regulations 2023, please click HERE